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Abstract
Oral cavity cancer (OC) has steadily decreased in the United States (US) since 1973 whereas 
oropharyngeal cancer (OP) has increased. We analyzed OC and OP cases from the Oklahoma 
Central Cancer Registry and Surveillance, Epidemiology, and End Results program comparing 
those diagnosed from 1997–1999 to those diagnosed from 2010–2012. We compared the incidence 
of OC and OP cases between Oklahoma and the US and by demographic factors. We observed an 
increase in OP cases, but no change in OC cases in both the US and in Oklahoma, and observed 
some differences between Oklahoma and the US by race, gender, and age group. A possible 
explanation for the increasing incidence of OP cancers may be the increasing prevalence of HPV. 
This study highlighted the differences in temporal trends of OC and OP cancers and the 
importance of changing risk factors for these cancers.
INTRODUCTION
While uncommon, head and neck cancers are associated with several modifiable risk factors, 
including tobacco, alcohol, and infection with a high risk human papilloma virus (HPV) 
strain.1 Cancers arising from the paranasal sinuses, nasal cavity, salivary glands, oral cavity, 
oropharynx, nasopharynx, hypopharynx, and larynx are collectively referred to as head and 
neck cancers.2,3 Etiology, risk factors, incidence, treatment, and mortality vary for each site. 
Squamous cell carcinoma (SCC) is the most common cancer of the head and neck,1 but the 
incidence has decreased over the past 30 years.4 Unlike oral cavity (OC) and other head and 
neck cancer sites, the incidence of oropharyngeal (OP) SCC, however, has increased.4,5 
Traditionally, most patients diagnosed with head and neck SCC were older and 90% of those 
diagnosed with oral cancer had a history of tobacco and/or alcohol use,4,6 but the 
characteristics of the head and neck cancer patient have changed over time.4 This change has 
been attributed to changes in social behaviors and the increase in prevalence of the HPV.7
Prior to the investigation of HPV, studies reported primarily tobacco and alcohol usage as a 
risk factors for both OC and OP cancers. While not completely understood, it is speculated 
that alcohol becomes a solvent for the carcinogenic cigarette smoke and allows for better 
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absorption through the mucosal layer.3,8 Tobacco has long been a known risk factor for OC 
and OP cancers,1 with a strong dose-response effect.8 Current cigarette smokers compared to 
never-smokers were 8.53 (95% CI: 3.38, 21.55) times more likely to develop oro-/
hypopharyngeal cancer, a cancer involving the oropharynx and/or the hypopharynx.3 
Additionally, former smokers were at an increased risk of oro-/hypopharyngeal compared to 
never-smokers.3 Studies have also reported a positive multiplicative interaction when 
cigarette use and alcohol use were combined.1,3,9 Heavy drinkers that smoke ≥20 cigarettes 
per day were 8.28 (95% CI: 3.98, 17.22) times more likely to develop head and neck cancer 
than never-smoker/non-drinkers.3
Regarding alcohol as an individual risk factor, the International Agency for Research on 
Cancer (IARC) has identified ethanol alcohol as a human carcinogen.8 In a study by 
Maasland et al, those with heavy alcohol consumption (≥30 g per day) compared to those 
with no alcohol consumption were 6.39 (95% CI 3.13, 13.03) times more likely to develop 
oral cavity cancer and 3.52 (95% CI 1.69, 7.36) times more likely to develop oro-/
hypopharyngeal cancer.3 The odds of OP cancer increases with both increased dose and 
increased duration of alcohol consumption.10
HPV is another known risk factor for OP cancers, particularly for SCC, according to 
IARC.8,7,11 While HPV is not currently listed as a risk factor for OC cancer by IARC, HPV 
has been implicated in the development of OC cancer.7 Cancer is induced by inactivating the 
tumor suppressor gene TP53, which aids in the up-regulation of squamous cell carcinoma.10 
The high-risk strains most notably associated with cervical cancers are HPV-16 and 
HPV-18.11 Oral HPV infection is assumed to be a sexually transmitted infection.12 In a 
study by Tezel et al, 70% of the base of tongue tumors, which are included in OP cancers, 
were HPV-16 positive, while none were positive for HPV-18.13 HPV-16 is most strongly 
associated with head and neck squamous cell carcinoma, which includes OP and OC cases 
(Adjusted Odds Ration [AOR]=18.3, 95% CI: 6.8, 49.0)10 Furthermore, Nasman et al 
observed that 74% of tonsillar or base of tongue SCC contained HPV DNA, with the most 
common strain being HPV-16 (84%). Oral cavity cancers were not evaluated in this study.12 
In contrast, a review of 60 studies reported only 35.6% of OP cancers were HPV positive 
and 23.5% of oral cavity cancers were HPV positive. Of those that were HPV positive, 87% 
of OP cancers and 68% of OC cancers were HPV-16 positive.9 While HPV-16 is the most 
common, high risk strains 31 and 33 have also been linked to OP SCC.14
Studies have indicated a reduced association between OP cancers and smoking and alcohol 
when HPV is present in patients. Non-smokers are 15 times more likely to present with HPV 
positive tumors than smokers.7 In a separate study, among the HPV-16 negative, the odds of 
oropharyngeal cancer was highest among those reporting greater than 50 packs years of 
smoking (AOR = 4.9, 95% CI: 2.1 to 11.3), those reporting 40–49 pack years (AOR = 3.2, 
95% CI: 1.1 to 9.0), and those reporting 20–39 pack years (AOR = 2.6, 95% CI: 1.3 to 5.1) 
compared to never smokers.10 Similar results were observed with alcohol use.7 HPV-16 
positive tumors in those with low tobacco exposure were biologically different and 
responded better to therapy than HPV-16 negative tumors of heavy drinkers and smokers.1 
Additionally, Mehta, Yu, and Schantz observed that survival for less differentiated tumors 
Denson et al. Page 2













increased by 57% compared to only 15.5% increase in survival for well-differentiated OC 
and OP tumors.7
Comparison of previous studies has been difficult due to lack of a standardized case 
definition.15 Each cancer site has different risk factors and how they are grouped together 
will dictate the trends observed. The purpose of this study was to evaluate the distribution of 
OC and OP cancers in Oklahoma and the US by grouping cancers based on risk factors 
instead of anatomical locations.15
METHODS
To examine incidence of OC and OP cancers in Oklahoma, we analyzed data from the 
Oklahoma Central Cancer Registry (OCCR). The OCCR is a part of the National Program of 
Central Registries (NPCR) of the Centers for Disease Control and Prevention (CDC). The 
registry has catalogued all cancers in Oklahoma residents since January 1, 1997. We 
included those with OP and OC cancers using SEER site recodes based on ICD-O-3/WHO 
2008 diagnosed from 1997–2012 (Table 1).16 We excluded lymphomas, mesotheliomas, and 
Kaposi sarcoma from all sites. To avoid misclassification, lip not otherwise specified (NOS), 
pharynx NOS, tongue NOS, palate NOS, and mouth NOS were excluded. Analyses of 
Oklahoma data were conducted in SAS (Cary, NC, version 9.4).
To obtain OC and OP incidence rates for the US, we used SEER*Stat software (Surveillance 
Research Program, National Cancer Institute, version 8.2.1). The Surveillance, 
Epidemiology, and End Results (SEER) Program, of the National Cancer Institute, has 
cancer data available from 1973 to 2012 and collects cancer data from cancer registries 
across the US designed to be representative of the US.17
To evaluate changes in incidence over time, we compared data from 1997–1999 and 2010–
2012 in Oklahoma to the US by age group, race, and gender. Age was grouped into five-year 
age groups, with those 85 and older combined. Comparisons by age were limited to those 35 
and older due to limited cases among younger age groups (<2% of OC cancers and <1% of 
OP cancers). In the Oklahoma data, we used the primary race variable to classify race and 
linked the data with Indian Health Service (IHS) records to reduce misclassification among 
the American Indian/Alaska Native population.
This study was approved by the Institutional Review Boards of the University of Oklahoma 
Health Sciences Center and the Oklahoma State Department of Health.
RESULTS
Overall
As observed in Figure 1, the age-adjusted incidence rate (AAIR) of OC cancer appears to 
have decreased from 3.7 (95% CI: 3.4, 4.1) in 1973 to 3.2 (95% CI: 3.0, 3.4) in 2012 in the 
US, whereas the AAIR of OP cancer has increased from 3.0 (95% CI: 2.7, 3.3) in 1973 to 
4.4 (4.2, 4.7) in 2012. When comparing OC and OP cancer in Oklahoma, the AAIR of OP 
cancer appears to have increased over time, whereas the AAIR of OC cancer appears stable, 
resulting in a widening gap between OC and OP cancer incidence over time (Figure 2). 
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There was no change in the OC cancer incidence rate in Oklahoma, but we observed an 
increase in the age-adjusted OP cancer incidence from 3.2 (95% CI: 2.6, 3.8) per 100,000 in 
1997 to 5.1 (95% CI: 4.4, 5.8) per 100,000 in 2012.
Oral Cavity Cancer—From 1997–1999 to 2010–2012 in the US, the AAIR of OC cancer 
decreased for Caucasians from 3.6 to 3.1 per 100,000 and African Americans from 3.4 to 2.3 
per 100,000, but remained stable among American Indian/Alaska Natives and Asian/Pacific 
Islanders (Table 2). The AAIR for OC cancer in Oklahoma remained stable for Caucasians, 
African Americans, and American Indian/Alaska Natives during this time frame. We were 
unable to compare the AAIR for Asian/Pacific Islanders in Oklahoma as no cases occurred 
from 1997–1999. Regarding differences by gender, the AAIR of OC cancer in the US 
decreased among males from 4.5 to 3.6 per 100,000 and among females from 2.6 to 2.3 per 
100,000. In Oklahoma, the AAIRs for OC cancer remained stable in both males and 
females. The AAIR of OC cancer in the US significantly decreased in the 65–69 age group 
from 13.0 to 9.8 per 100,000, but remained stable in Oklahoma.
Oropharyngeal Cancer—From 1997–1999 to 2010–2012, OP cancer AAIR in the US 
increased in Caucasians from 3.4 to 4.7 per 100,000 (Table 3). The AAIR decreased in 
African Americans from 5.2 to 3.8 per 100,000, but remained stable in American Indian/
Alaska Natives and Asian/Pacific Islanders. Similar to the US, the AAIR of OP cancer in 
Oklahoma increased among Caucasians from 3.2 to 5.0 per 100,000, while the AAIR 
remained stable among African Americans and Asian/Pacific Islanders. Although not 
statistically significant, the AAIR for the American Indian/Alaska Native population in 
Oklahoma increased from 2.7 to 5.2 per 100,000 during the time frame. The incidence rates 
of OP cancers in the US remained relatively stable in females, but increased in males from 
5.4 to 7.0 per 100,000. Similarly, the incidence of OP cancer in Oklahoma in males 
increased from 5.1 to 8.2 per 100,000, but remained stable among females. Regarding 
differences by age group, the AAIR of OP cancer in the US increased in most age groups, 
but only significantly among those between 50 and 69 years of age, which was similar to 
rates observed in Oklahoma.
DISCUSSION
This study examined trends in the incidence of OC and OP cancers in both Oklahoma and 
the US. The longitudinal data confirm that the incidence of head and neck cancers vary by 
site in both Oklahoma and the US. Specifically, we observed that the incidence of OC 
declined over time while OP cancers increased in the US. OP cancers have also increased in 
Oklahoma while there has been no change in the incidence of OC cancers. In general, the 
trends in Oklahoma by time, race, sex, and age are similar to those in the US.
It is likely OC and OP cancers now consist of two separate etiologic pathways: those made 
up of cancers associated with alcohol and tobacco exposures and those more strongly 
associated with exposure to high risk HPV infection.18 While head and neck cancers due to 
alcohol and tobacco use have steadily decreased in the US since 1973, OP cancers have 
increased, likely due to the prevalence of HPV.2 Our study observed a decline in OC 
incidence in the US, which may suggest a decrease in alcohol and tobacco usage at the 
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national level, but this needs further investigation. While not forgetting the classic risk 
factors, health care providers must consider a new risk factor, HPV, and those at risk of HPV 
infection.
Changing social behaviors and prevalence of HPV have changed the demographics of the 
OC and OP cancer patient. HPV positive head and neck cancer patients are younger than the 
head and neck cancer patients of the past.4 Today a higher proportion of the head and neck 
cancer patients are younger white14 males that have limited or no alcohol/tobacco 
exposures2 as opposed to previous years where African Americans had a higher risk of these 
cancers.6 Recent head and neck cancer patients tend to have a history of increased sexual 
partners11 and specifically an increase in oral sex partners.4,9
This study had several strengths, one of which was that we were able to use data from 
population-based registries in Oklahoma and the US, which reduced the chance of selection 
bias. We were also able to select specific cancer sites to classify cases as having OC or OP 
cancer according to risk factors rather than anatomical sites due to the level of detail 
available from both sources of data. Furthermore, we used the same classifications to 
compare Oklahoma and US data based on the SEER registry.
However, there were also several limitations in this study. Both OC and OP are rare diseases, 
resulting in the need to combine multiple years for comparison. Furthermore, the rarity of 
these diseases lead to imprecision in the AAIR estimates so some true differences may be 
masked. We observed a nonsignificant increase in OP cancer among American Indians/
Alaska Natives in Oklahoma, with little difference in the US data. SEER is designed to be 
representative of the US population.19 However, the American Indian/Alaska Native 
population in SEER primarily originates from the New Mexico and Alaska SEER registries, 
which are not necessarily representative of all American Indians/Alaska Natives in the US.20 
Using IHS-linked data to estimate the AAIR of both OC and OP cancer in the US would 
provide a better comparison to the Oklahoma data. The study required the ability to identify 
specific sites of OP and OC cancers, which was not available using the data available in the 
CDC’s Wide-ranging Online Data for Epidemiologic Research (WONDER) database.21
In summary, while the AAIR of both OP and OC cancers is similar in the US and Oklahoma, 
the incidence of OP cancers has increased, which may be related to increasing prevalence of 
HPV. This study highlighted the differences in trends of OC and OP cancers over time and 
the importance of changing risk factors for these cancers, primarily OP cancers. The 
relationship between OC and OP cancers becomes increasingly complex in individuals who 
smoke, drink and have HPV.1 More studies are needed to understand the interaction between 
an established HPV infection and modifiable risk factors such as smoking and drinking. In 
addition future studies evaluating the differences in smoking, alcohol, and HPV status 
among OC and OP cancer cases by gender, race, and age are recommended to better 
understand the importance of these modifiable risk factors.
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Figure 1. Age-adjusted incidence rates of oral cavity (OC) and oropharyngeal (OP) cancers in 
the US from 1973 to 2012
Source: Surveillance, Epidemiology, and End Results (SEER) Program 
(www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 
2014 Sub (1973–2012) <Katrina/Rita Population Adjustment> - Linked To County 
Attributes - Total U.S., 1969–2013
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Age-adjusted incidence rates of oral cavity (OC) cancer and oropharyngeal (OP) cancer in 
Oklahoma from 1997–2012.
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Table 1
Oropharyngeal and Oral Cavity Cancer Site Recodes.16
Oropharyngeal Cancer Site Recodes Oral Cavity Cancer Site Recodes
Site Recode Site Recode
Base of tongue C01.9 Mucosa of upper lip C00.3
Lingual tonsils C02.4 Mucosa of lower lip C00.4
Overlapping lesions of the tongue C02.8 Mucosa of lip NOS C00.5
Soft palate not otherwise specified (NOS) C05.1 Overlapping lesion of the lip C00.8
Uvula C05.2 Dorsal surface of tongue C02.0
Overlapping lesion of the palate C05.8 Border of tongue C02.1
Tonsillar fossa C09.0 Ventral surface of tongue C02.2
Tonsillar pillar C09.1 Anterior two-thirds tongue C02.3
Overlapping lesion of the tonsils C09.8 Overlapping lesion of tongue C02.8
Tonsils NOS C09.9 Upper gum C03.0
Lateral walls of the oropharynx C10.2 Lower gum C03.1
Posterior walls of the oropharynx C10.3 Gum NOS C03.9
Overlapping lesion of the oropharynx C10.8 Anterior floor of mouth C04.0
Oropharynx NOS C10.9 Lateral floor of mouth C04.1
Waldeyer’s ring C14.2 Overlapping lesion of floor of mouth C04.8
Floor of mouth NOS C04.9
Hard palate C05.0
Overlapping lesion of palate C05.8
Cheek mucosa C06.0
Retromolar area C06.2
Overlapping lesion other C06.8
Overlapping lesion of lips and oral cavity C14.8
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Table 2
Age-adjusted incidence rates of oral cavity cancer in the US and Oklahoma in 1997–1999 and 2010–2012.
OK US
1997–1999 2010–2012 1997–1999 2010–2012
Characteristic Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Race
 White 2.6 (2.3, 2.9) 2.6 (2.3, 2.9) 3.6 (3.5, 4.0) 3.1 (3.0, 3.3)
 African American 2.4 (1.1, 3.8) 2.8 (1.6, 4.1) 3.4 (3.1, 3.8) 2.3 (2.0, 2.6)
 American Indian/Alaska Native 3.2 (1.7, 4.8) 2.4 (1.4, 3.4) 1.9 (1.1, 3.1) 1.8 (1.2, 2.5)
 Asian/Pacific Islander N/Aa 2.4 (0.0, 5.4) 2.2 (1.9, 2.5) 2.0 (1.8, 2.2)
Gender
 Male 3.3 (2.8, 3.9) 3.3 (2.8, 3.7) 4.5 (4.3, 4.7) 3.6 (3.5, 3.8)
 Female 2.0 (1.6, 2.3) 1.9 (1.6, 2.2) 2.6 (2.5, 2.7) 2.3 (2.2, 2.4)
Age
 35–39 0.6 (0.1, 1.2) 1.0 (0.3, 1.8) 0.9 (0.7, 1.1) 0.9 (0.7, 1.1)
 40–44 2.3 (1.2, 3.4) 1.4 (0.5, 2.3) 1.7 (1.4, 1.9) 1.4 (1.1, 1.6)
 45–49 3.2 (1.9, 4.5) 2.5 (1.4, 3.7) 3.1 (2.8, 3.6) 2.7 (2.3, 3.0)
 50–54 5.2 (3.4, 7.0) 4.1 (2.7, 5.6) 5.4 (4.8, 6.0) 4.7 (4.3, 5.2)
 55–59 5.5 (3.5, 7.6) 7.4 (5.4, 9.4) 7.8 (7.0 8.6) 6.9 (6.3, 7.5)
 60–64 6.2 (3.8, 8.6) 5.2 (3.4, 7.0) 10.1 (9.1, 11.1) 7.5 (6.9, 8.2)
 65–69 8.2 (5.4, 11.1) 8.5 (5.9, 11.0) 13.0 (11.8, 14.2) 9.8 (8.9, 10.7)
 70–74 8.2 (5.2, 11.3) 11.2 (7.8, 14.6) 13.7 (12.4, 15) 11.3 (10.2, 12.5)
 75–80 10.1 (6.4, 13.9) 11.8 (7.8, 15.8) 16.1 (14.6, 17.7) 13.9 (12.5, 15.4)
 80–84 14.1 (8.7, 19.6) 11.0 (6.5, 15.5) 16.8 (15.0, 18.8) 13.9 (12.4, 15.6)
 85+ 11.2 (6.2, 16.3) 10.4 (5.9, 15.0) 15.9 (13.9, 18) 15.3 (13.8, 17.1)
a
No cases observed
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Table 3
Age-adjusted incidence rates of oropharyngeal cancer in the US and Oklahoma in 1997–1999 and 2010–2012.
OK US
1997–1999 2010–2012 1997–1999 2010–2012
Characteristic Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Age-Adjusted 
Incidence Rate per 
100,000 (95% CI)
Race
 White 3.2 (2.8, 3.5) 5.0 (4.6, 5.5) 3.4 (3.3, 3.6) 4.7 (4.5, 4.8)
 African American 4.5 (2.8, 6.3) 3.3 (1.9, 4.6) 5.2 (4.8, 5.7) 3.8 (3.5, 4.2)
 American Indian/Alaska Native 2.7 (1.4, 3.9) 5.2 (3.7, 6.7) 2.3 (1.4, 3.5) 2.7 (2.0, 3.6)
 Asian/Pacific Islander 1.9 (0.0, 4.4) 0.4 (0.0, 1.2) 2.0 (1.7, 2.3) 1.7 (1.5, 2.0)
Gender
 Male 5.1 (4.4, 5.7) 8.2 (7.5, 9.0) 5.4 (5.2, 5.6) 7.0 (6.8, 7.2)
 Female 1.6 (1.3, 1.9) 1.7 (1.4, 2.0) 1.8 (1.7, 1.9) 1.7 (1.6, 1.8)
Age
 35–39 0.9 (0.2, 1.5) 0.9 (0.2, 1.6) 0.9 (0.7, 1.1) 0.6 (0.5, 0.8)
 40–44 2.7 (1.6, 3.9) 3.4 (2.1, 4.8) 2.0 (1.7, 2.3) 2.1 (1.8, 2.4)
 45–49 6.1 (4.3, 8.0) 8.0 (6.0, 10.0) 4.6 (4.1, 5.1) 5.1 (4.7, 5.6)
 50–54 7.7 (5.5, 9.9) 12.3 (9.9, 14.7) 7.3 (6.6, 8.0) 9.3 (8.7, 10.0)
 55–59 9.2 (6.5, 11.9) 15.0 (12.1, 17.8) 9.4 (8.5, 10.3) 12.9 (12.1, 13.7)
 60–64 8.8 (6.0, 11.7) 16.6 (13.4, 19.7) 10.8 (9.8, 11.9) 16.5 (15.5, 17.5)
 65–69 10.8 (7.5, 14.1) 21.2 (17.1, 25.2) 12.2 (11.0, 13.4) 15.9 (14.8, 17.0)
 70–74 12.4 (8.6, 16.1) 11.5 (8.1, 14.9) 14.8 (13.5, 16.2) 14.9 (13.6, 16.2)
 75–80 7.2 (4.1, 10.4) 12.8 (8.7, 17.0) 11.6 (10.3, 12.9) 13.4 (12.1, 14.9)
 80–84 8.7 (4.4, 13.0) 12.4 (7.7, 17.2) 10.4 (9.0, 12.0) 11.6 (10.2, 13.1)
 85+ 4.1 (1.1, 7.2) 4.2 (1.3, 7.1) 8.0 (6.6, 9.6) 8.0 (6.9, 9.2)
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